The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials

Background People with schizophrenia spectrum disorders (SSDs) experience high rates of obesity and metabolic dysfunction, contributing substantially to excess morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have demonstrated subst...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Mike Trott, Urska Arnautovska, Donni Johnston, Gabrielle Ritchie, Dan Siskind
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Cambridge University Press 2026-05-01
Reeks:	BJPsych Open
Onderwerpen:	Psychotic disorders/schizophrenia randomised controlled trial clinical trials systematic review meta-analysis
Online toegang:	https://www.cambridge.org/core/product/identifier/S2056472426120018/type/journal_article
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!